Kosan Biosciences Inc. and Roche Holding AG ended their five-year collaboration to develop and commercialize epothilones, anticancer agents that inhibit cell division. (BioWorld Today)

The phrase "rheumatoid arthritis" almost right away calls to mind Genentech Inc.'s Rituxan (rituximab, which targets the CD20 antigen, for RA and non-Hodgkin's lymphoma). (BioWorld Financial Watch)